title: The exposure of cancer cells to hyperthermia, iron oxide nanoparticles, and mitomycin C influences membrane multidrug resistance protein expression levels.
abstract: OBJECTIVE
  The presence of multidrug resistance-associated protein (MRP) in cancer cells is known to be responsible for many therapeutic failures in current oncological treatments. Here, we show that the combination of different effectors like hyperthermia, iron oxide nanoparticles, and chemotherapeutics influences expression of MRP 1 and 3 in an adenocarcinoma cell line.
  
  
  METHODS
  BT-474 cells were treated with magnetic nanoparticles (MNP; 1.5 to 150 μg Fe/cm(2)) or mitomycin C (up to 1.5 μg/cm(2), 24 hours) in the presence or absence of hyperthermia (43°C, 15 to 120 minutes). Moreover, cells were also sequentially exposed to these effectors (MNP, hyperthermia, and mitomycin C). After cell harvesting, mRNA was extracted and analyzed via reverse transcription polymerase chain reaction. Additionally, membrane protein was isolated and analyzed via sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotting.
  
  
  RESULTS
  When cells were exposed to the effectors alone or to combinations thereof, no effects on MRP 1 and 3 mRNA expression were observed. In contrast, membrane protein expression was influenced in a selective manner. The effects on MRP 3 expression were less pronounced compared with MRP 1. Treatment with mitomycin C decreased MRP expression at high concentrations and hyperthermia intensified these effects. In contrast, the presence of MNP only increased MRP 1 and 3 expression, and hyperthermia reversed these effects. When combining hyperthermia, magnetic nanoparticles, and mitomycin C, no further suppression of MRP expression was observed in comparison with the respective dual treatment modalities.
  
  
  CONCLUSIONS
  The different MRP 1 and 3 expression levels are not associated with de novo mRNA expression, but rather with an altered translocation of MRP 1 and 3 to the cell membrane as a result of reactive oxygen species production, and with shifting of intracellular MRP storage pools, changes in membrane fluidity, etc, at the protein level. Our results could be used to develop new treatment strategies by repressing mechanisms that actively export drugs from the target cell, thereby improving the therapeutic outcome in oncology.
authors: Institute of Diagnostic and Interventional Radiology, Department of Experimental Radiology, Institute of Diagnostic and Interventional Radiology I, University Hospital Jena, Friedrich-Schiller Universität Jena, Jena, Germany.
authors: Karolin
authors: K
authors: Franke
authors: Melanie
authors: M
authors: Kettering
authors: Kathleen
authors: K
authors: Lange
authors: Werner A
authors: WA
authors: Kaiser
authors: Ingrid
authors: I
authors: Hilger
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000378:metabolism / Q000628:therapy; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism / Q000628:therapy*; D045744:Cell Line, Tumor; D003131:Combined Modality Therapy; D019008:Drug Resistance, Neoplasm; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D006979:Hyperthermia, Induced / Q000379:methods*; D058185:Magnetite Nanoparticles / Q000008:administration & dosage* / Q000737:chemistry; D016685:Mitomycin / Q000494:pharmacology*; D027425:ATP-Binding Cassette, Sub-Family C Proteins / Q000096:biosynthesis / Q000235:genetics / Q000378:metabolism*; D018709:Statistics, Nonparametric
chemical_list: D000903:Antibiotics, Antineoplastic; D058185:Magnetite Nanoparticles; D016685:Mitomycin; D027425:ATP-Binding Cassette, Sub-Family C Proteins
keywords: MDR; MRP; cancer; chemotherapy; drugs; hyperthermia; iron oxide; magnetic nanoparticles; nanotechnology
references: Proc Natl Acad Sci U S A. 2004 Feb 24;101(8):2470-5
references: 14983033
references: Cancer Res. 1995 Jan 1;55(1):102-10
references: 7805019
references: Crit Rev Oncol Hematol. 2002 Jul;43(1):33-56
references: 12098606
references: Mol Pharmacol. 2005 Aug;68(2):430-8
references: 15901850
references: Int J Nanomedicine. 2009;4:73-8
references: 19421372
references: Biochemistry (Mosc). 2008 May;73(5):592-604
references: 18605983
references: J Nanosci Nanotechnol. 2007 Aug;7(8):2933-7
references: 17685322
references: Prostate. 2006 May 15;66(7):718-27
references: 16425185
references: Cancer Treat Res. 2007;134:171-84
references: 17633053
references: Redox Rep. 2006;11(4):173-8
references: 16984740
references: Biochim Biophys Acta. 2009 May;1794(5):725-37
references: 19135557
references: J Biol Chem. 2001 May 18;276(20):17420-8
references: 11279018
references: FEBS Lett. 2005 Aug 15;579(20):4541-4549
references: 16083877
references: Mol Biol Cell. 2003 Aug;14(8):3389-99
references: 12925771
references: Antioxid Redox Signal. 2009 Jan;11(1):99-133
references: 18699730
references: Int J Nanomedicine. 2010 Nov 16;5:983-9
references: 21187917
references: Int J Nanomedicine. 2009;4:107-14
references: 19516889
references: Oncol Rep. 2007 Jul;18(1):219-26
references: 17549371
references: Leukemia. 1997 Jul;11(7):945-9
references: 9204973
references: Carcinogenesis. 1999 Mar;20(3):407-14
references: 10190554
references: Cancer Biol Ther. 2007 Nov;6(11):1794-9
references: 18032928
references: Toxicol Appl Pharmacol. 2005 May 1;204(3):216-37
references: 15845415
references: News Physiol Sci. 2004 Feb;19:11-5
references: 14739396
references: Cancer Res. 1979 Jun;39(6 Pt 2):2277-84
references: 376117
references: Cancer Biol Ther. 2008 Mar;7(3):468-75
references: 18285700
references: Chemotherapy. 2010;56(1):9-16
references: 20185911
references: J Biol Chem. 1990 Jan 5;265(1):221-6
references: 1967174
references: Biomaterials. 2011 Dec;32(35):9401-14
references: 21911251
references: Taiwan J Obstet Gynecol. 2009 Sep;48(3):239-44
references: 19797012
references: Biochem Biophys Res Commun. 1992 Sep 16;187(2):677-84
references: 1356336
references: J Biomed Mater Res A. 2011 Jan;96(1):186-95
references: 21105167
references: Eur J Cancer. 2008 Nov;44(17):2546-54
references: 18789678
references: Pflugers Arch. 2007 Feb;453(5):621-41
references: 17187268
references: J Nanosci Nanotechnol. 2007 Dec;7(12):4604-6
references: 18283851
references: Mol Cell Biochem. 1996 Jun 7;159(1):25-31
references: 8813706
references: J Control Release. 2010 Feb 25;142(1):89-100
references: 19815037
references: Trends Biochem Sci. 2010 Jan;35(1):36-42
references: 19819701
references: Oncogene. 2003 Oct 20;22(47):7537-52
references: 14576857
references: J Bioenerg Biomembr. 2001 Dec;33(6):493-501
references: 11804191
references: Biochem Pharmacol. 1998 Mar 1;55(5):605-15
references: 9515571
references: Int J Cancer. 1998 Mar 30;76(1):55-62
references: 9533762
references: J Urol. 2005 Apr;173(4):1375-80
references: 15758808
references: J Pharm Sci. 2010 Feb;99(2):1087-98
references: 19623615
references: Int J Nanomedicine. 2008;3(2):277-86
references: 18686787
references: Int J Cancer. 2005 Jan 10;113(2):229-40
references: 15389514
references: Ann Oncol. 2002 Aug;13(8):1173-84
references: 12181239
references: Toxicology. 2011 May 10;283(2-3):101-8
references: 21382431
references: Cancer Treat Res. 2007;134:185-93
references: 17633054
references: Int J Hyperthermia. 2007 Feb;23(1):3-15
references: 17575719
references: Am J Physiol Cell Physiol. 2001 May;280(5):C1031-7
references: 11287314
references: J Biochem Mol Toxicol. 1998;12(6):325-37
references: 9736481
references: J Pharmacol Exp Ther. 2001 Nov;299(2):483-93
references: 11602658
references: J Biol Chem. 2000 Aug 11;275(32):24970-6
references: 10816597
references: Clin Cancer Res. 1997 Aug;3(8):1339-46
references: 9815817